Business
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring
Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research‑use‑only (RUO) blood test for post‑treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc. (“EG BioMed”)’s CLIA/CAP‑certified laboratory in the Un
About this update from Yd Bio Limited
[{"type":"image","alt":"YD Bio Limited","displaySize":"","headline":null,"caption":"YD Bio Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":34,"url":"https://media.zenfs.com/en/globenewswire.com/2adf5e709359305c92390744828dcf90"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XsrmpkDOCpNlqxSqRr4r1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTQ2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2adf5e709359305c92390744828dcf90","width":82,"height":34}},"lazy":false},{"type":"text","content":"Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its support for the global commercialization of OkaiDx™, a research‑use‑only (RUO) blood test for post‑treatment breast cancer monitoring now available through the Company’s affiliate EG Biomed US Inc. (“EG BioMed”)’s CLIA/CAP‑certified laboratory in the United States. YD Bio’s role is to support commercialization efforts for OkaiDx™ under the authorization granted to the Company, working alongside EG BioMed to make the assay accessible to research laboratories, academic groups and industry partners conducting surveillance and translational studies.","length":798,"tagName":"p"},{"type":"text","content":"OkaiDx™ was developed through international scientific collaboration and uses cfDNA methylation profiling to generate molecular surveillance information for research settings. The test has been reported in peer‑reviewed journals such as Clinical Epigenetics and Biomolecules, and presented at major oncology conferences. EG BioMed’s CLIA and CAP accreditation enables U.S. testing and reporting of RUO assays in an accredited laboratory environment, while YD Bio’s support complements EG BioMed’s laboratory capabilities by helping coordinate commercialization, researcher engagement and sample logistics for study use.","length":619,"tagName":"p"},{"type":"text","content":"YD Bio’s involvement follows its ongoing partnership activities with EG BioMed to expand U.S. laboratory access for cutting‑edge molecular assays, said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio Limited. “Independent validation already reported performance metrics of 95.1% accuracy, 89.4% sensit...